Gyre Therapeutics, Inc. (GYRE)

6.59 -1.35% (-0.09)

Over 5Y: -83.6%

2026-08-28
20 40
2021 2022 2023 2024 2025 2026

Financials Quarterly

Q3 '21 — Revenue: 2.3M Q3 '21 — Operating Cash Flow: -21.6M Q3 '21 — Free Cash Flow: -22.1M Q3 '21 — Net Income: -25.2M Q4 '21 — Revenue: 2.4M Q4 '21 — Operating Cash Flow: -17.7M Q4 '21 — Free Cash Flow: -17.7M Q4 '21 — Net Income: -20.3M Q1 '22 — Revenue: 794K Q1 '22 — Operating Cash Flow: -12.1M Q1 '22 — Net Income: -14.5M Q2 '22 — Operating Cash Flow: -12.3M Q2 '22 — Net Income: 51.6M Q3 '22 — Operating Cash Flow: -7.3M Q3 '22 — Net Income: -4.9M Q4 '22 — Operating Cash Flow: 42.3M Q4 '22 — Net Income: -27.9M Q1 '23 — Revenue: 24.9M Q1 '23 — Operating Cash Flow: 10.4M Q1 '23 — Free Cash Flow: 8.7M Q1 '23 — Net Income: 4.2M Q2 '23 — Revenue: 29.3M Q2 '23 — Operating Cash Flow: 4.5M Q2 '23 — Free Cash Flow: 2.1M Q2 '23 — Net Income: 3.8M Q3 '23 — Revenue: 32M Q3 '23 — Operating Cash Flow: 7.6M Q3 '23 — Free Cash Flow: 5.6M Q3 '23 — Net Income: 7.5M Q4 '23 — Revenue: 27.1M Q4 '23 — Operating Cash Flow: 3.4M Q4 '23 — Free Cash Flow: 1M Q4 '23 — Net Income: -81.7M Q1 '24 — Revenue: 27.2M Q1 '24 — Operating Cash Flow: 2.9M Q1 '24 — Free Cash Flow: 2.7M Q1 '24 — Net Income: 9.9M Q2 '24 — Revenue: 25.2M Q2 '24 — Operating Cash Flow: -5.5M Q2 '24 — Free Cash Flow: -6.9M Q2 '24 — Net Income: 4.5M Q3 '24 — Revenue: 25.5M Q3 '24 — Operating Cash Flow: 1.7M Q3 '24 — Free Cash Flow: 1M Q3 '24 — Net Income: 2.9M Q4 '24 — Revenue: 27.9M Q4 '24 — Operating Cash Flow: -2.8M Q4 '24 — Free Cash Flow: -2.8M Q4 '24 — Net Income: 598K Q1 '25 — Revenue: 22.1M Q1 '25 — Operating Cash Flow: -129K Q1 '25 — Free Cash Flow: -251K Q1 '25 — Net Income: 4.9M Q2 '25 — Revenue: 29.7M Q2 '25 — Operating Cash Flow: -7.5M Q2 '25 — Free Cash Flow: -7.8M Q2 '25 — Net Income: -2.2M Q3 '25 — Revenue: 30.6M Q3 '25 — Operating Cash Flow: 14.2M Q3 '25 — Free Cash Flow: 13.6M Q3 '25 — Net Income: 5.9M Q4 '25 — Revenue: 37.2M Q4 '25 — Operating Cash Flow: -5.6M Q4 '25 — Free Cash Flow: -5.8M Q4 '25 — Net Income: 1.2M Q1 '26 — Revenue: 22.5M Q1 '26 — Operating Cash Flow: 3.2M Q1 '26 — Free Cash Flow: 3M Q1 '26 — Net Income: -18.6M Q2 '26 — Revenue: 29.1M Q2 '26 — Operating Cash Flow: -16.7M Q2 '26 — Free Cash Flow: -17M Q2 '26 — Net Income: -14.3M -60M -30M 0 30M 60M
Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

1.9
OE margin -13.4%
Oper. margin -14.0%
ROIC -26.0%
Accruals -10.4%
Gross margin 85.8%
EBITDA margin -11.4%
FCF margin -5.1%
OCF margin -4.1%
Profit margin -21.5%
ROA -12.9%
ROCE -9.8%
ROE -23.8%
OCF / EBIT —

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

2.9
RPO / sales 0.0002×
RPO growth —
Segment HHI —

4 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

9.7
Cash runway 9.4 yr
ND/EBITDA —
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 3.9×
F-score 4.5 pts
Cash / Debt —
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

4.2
Sales CAGR 4Y +99.6%
Sales/sh Y/Y +12.6%
Shares change +0.87%
EPS Y/Y -513.4%
Sales Q/Q -2.1%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.